Phase 1 Relapsing Multiple Sclerosis Clinical Trials

4 recruitingPhase 1

What is a Phase 1 trial?

Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.

Showing 1–4 of 4 trials

Recruiting

Phase 1Phase 2

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

Novartis Pharmaceuticals28 enrolled18 locationsNCT06617793

Withdrawn

Phase 1

Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fed conditions in healthy male and female volunteers.

Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Zenith Technology Corporation Limited39 enrolled1 locationACTRN12621000887875

Withdrawn

Phase 1

Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fasting condition in healthy male and female volunteers.

Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Zenith Technology Corporation Limited39 enrolled1 locationACTRN12621000775819

Completed

Phase 1

Comparative assessment of the absorption of a generic formulation of dimethyl fumarate capsule against the innovator dimethyl fumarate capsule conducted under fasting condition in healthy male and female volunteers.

Dimethyl fumarate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Zenith Technology Corporation Limited12 enrolled1 locationACTRN12619000576123